Grants and Contributions:
Title:
CAR-NK optimization through delivery of CRISPRa to safe harbours that enable persistent transgene expression during iPSCs differentiation
Agreement Number:
1000903
Agreement Value:
$200,000.00
Agreement Date:
Mar 23, 2023 - Mar 31, 2026
Description:
Specialized cells called induced pluripotent stem cells (iPSCs) are derived from mature tissue, such as the skin, and have accelerated the development of cell-based therapies for neurodegenerative disorders, cancer, and other hard-to-treat diseases. However, the processes used to convert cells taken from a patient into a therapeutic product could be more efficient and easier to control. The project focuses on iPSC-derived CAR-NK immune cells, an upcoming anticancer therapy technology in which cells from a patient are modified and reintroduced to stimulate the patient's anticancer immune defences. Previous studies show that current production methods yield a low number of CAR-NK cells and that these cells rapidly lose their therapeutic attributes. The project investigates if new genome engineering strategies can improve the production of iPSC-derived CAR-NK immune cells. It has the potential to set new standards for stem cell manipulation and iPSC-derived therapy production that will bring CAR-NK anticancer therapies closer to the clinic.
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Location:
Ottawa, Ontario, CA K1N 6N5
Reference Number:
172-2022-2023-Q4-1000903
Agreement Type:
Grant
Report Type:
Grants and Contributions
Recipient Business Number:
119278877
Recipient Type:
Academia
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreement has been modified by 365 days.
Amendment Date
Apr 10, 2025
Recipient's Legal Name:
University of Ottawa
Federal Riding Name:
Ottawa--Vanier--Gloucester
Federal Riding Number:
35081
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
NAICS Code:
541710
Amendments: